84 related articles for article (PubMed ID: 17278710)
1. The molecular biology and immunology of glioblastoma multiforme (GBM) with the presentation of an immunotherapy protocol for a clinical trial.
Sinkovics JG; Horvath JC
Acta Microbiol Immunol Hung; 2006 Dec; 53(4):367-429. PubMed ID: 17278710
[TBL] [Abstract][Full Text] [Related]
2. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma multiforme: a review of where we have been and where we are going.
Adamson C; Kanu OO; Mehta AI; Di C; Lin N; Mattox AK; Bigner DD
Expert Opin Investig Drugs; 2009 Aug; 18(8):1061-83. PubMed ID: 19555299
[TBL] [Abstract][Full Text] [Related]
4. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
Wheeler CJ; Das A; Liu G; Yu JS; Black KL
Clin Cancer Res; 2004 Aug; 10(16):5316-26. PubMed ID: 15328167
[TBL] [Abstract][Full Text] [Related]
5. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
6. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated?
McLendon RE; Halperin EC
Cancer; 2003 Oct; 98(8):1745-8. PubMed ID: 14534892
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy targeting glioma stem cells--insights and perspectives.
Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme.
Koka V; Potti A; Forseen SE; Pervez H; Fraiman GN; Koch M; Levitt R
Am J Clin Oncol; 2003 Aug; 26(4):332-5. PubMed ID: 12902879
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.
Wang L; Liu Q; Zhao H; Cui K; Yao L; Nie F; Jin G; Hao A; Wong ST
J Neurosci Res; 2013 Jan; 91(1):128-37. PubMed ID: 23115024
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
12. Effect of valproic acid on the outcome of glioblastoma multiforme.
Tsai HC; Wei KC; Tsai CN; Huang YC; Chen PY; Chen SM; Lu YJ; Lee ST
Br J Neurosurg; 2012 Jun; 26(3):347-54. PubMed ID: 22168970
[TBL] [Abstract][Full Text] [Related]
13. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme.
Jagannathan J; Prevedello DM; Dumont AS; Laws ER
Neurosurg Focus; 2006 Apr; 20(4):E8. PubMed ID: 16709039
[TBL] [Abstract][Full Text] [Related]
14. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.
Bambury RM; Morris PG
Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143
[TBL] [Abstract][Full Text] [Related]
15. Discovering gene-environment interactions in glioblastoma through a comprehensive data integration bioinformatics method.
Kunkle B; Yoo C; Roy D
Neurotoxicology; 2013 Mar; 35():1-14. PubMed ID: 23261424
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Reardon DA; Egorin MJ; Quinn JA; Rich JN; Gururangan S; Vredenburgh JJ; Desjardins A; Sathornsumetee S; Provenzale JM; Herndon JE; Dowell JM; Badruddoja MA; McLendon RE; Lagattuta TF; Kicielinski KP; Dresemann G; Sampson JH; Friedman AH; Salvado AJ; Friedman HS
J Clin Oncol; 2005 Dec; 23(36):9359-68. PubMed ID: 16361636
[TBL] [Abstract][Full Text] [Related]
17. [Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients].
Kubo O; Takakura K
Nihon Rinsho; 2002 Mar; 60(3):497-503. PubMed ID: 11904965
[TBL] [Abstract][Full Text] [Related]
18. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
[TBL] [Abstract][Full Text] [Related]
19. Spinal glioblastoma multiforme of the conus medullaris with holocordal and intracranial spread in a child: a case report and review of the literature.
Mori K; Imai S; Shimizu J; Taga T; Ishida M; Matsusue Y
Spine J; 2012 Jan; 12(1):e1-6. PubMed ID: 22197783
[TBL] [Abstract][Full Text] [Related]
20. Emerging patents in the therapeutic areas of glioma and glioblastoma.
Harris M; Svensson F; Kopanitsa L; Ladds G; Bailey D
Expert Opin Ther Pat; 2018 Jul; 28(7):573-590. PubMed ID: 29950117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]